KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) EBITDA (2016 - 2025)

Historic EBITDA for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $6.5 billion.

  • Pfizer's EBITDA rose 286.44% to $6.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 billion, marking a year-over-year increase of 3044400.0%. This contributed to the annual value of $17.8 billion for FY2024, which is 18689.98% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's EBITDA is $6.5 billion, which was up 286.44% from $5.1 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's EBITDA ranged from a high of $13.0 billion in Q3 2022 and a low of -$14.1 billion during Q4 2023
  • Moreover, its 5-year median value for EBITDA was $5.5 billion (2021), whereas its average is $3.5 billion.
  • As far as peak fluctuations go, Pfizer's EBITDA tumbled by 16739.68% in 2023, and later surged by 42644.16% in 2024.
  • Pfizer's EBITDA (Quarter) stood at $7.9 billion in 2021, then soared by 30.62% to $10.3 billion in 2022, then crashed by 236.89% to -$14.1 billion in 2023, then surged by 144.61% to $6.3 billion in 2024, then increased by 2.86% to $6.5 billion in 2025.
  • Its last three reported values are $6.5 billion in Q3 2025, $5.1 billion for Q2 2025, and $5.0 billion during Q1 2025.